Amylyx Pharmaceuticals (AMLX) Stock Price, Quote, News & History | Benzinga

Amylyx Pharmaceuticals Inc (AMLX) Stock Price, Quote, News & History

AMLXNASDAQ

Trade with Public

Trade with Public

$21.63

-0.85-3.78%

At close: Aug 14, 5:00 PM EST

$21.50

-0.13-0.6%

After Hours: 6:03 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$22.35

Close

$21.63

Volume / Avg.

1.59M / 1.64M

Day Range

$21.29 - $22.39

52 Wk Range

7.63 - 24.60

Market Cap

$2.39B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

57

Short Interest

15.62%

Days to Cover

6.84

Recent Amylyx Pharmaceuticals, Inc. News

Beyond Meat Posts Downbeat Q4 Results, Joins RH, ORIC Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

US stock futures higher with Dow up 200 pts, Beyond Meat shares drop after downbeat results; ORIC, RH, Aptiv, Sweetgreen, Nike, and others also decline.

Avi Kapoor

This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

Top Wall Street analysts changed outlook on top names. Check out analyst ratings page for all changes. AMLX, OFRM, AGMB, SGP initiated with positive outlook.

Avi Kapoor

Amylyx Halts Rare Brain Disorder Drug Program After Disappointing Trial

Amylyx ends its PSP trial for AMX0035 after no efficacy was seen and turns its focus to avexitide and ALS research, expecting data in 2025 and 2026.

Vandana Singh

Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery

Amylyx reports strong Phase 2b trial data for avexitide, showing 64% fewer hypoglycemic events in patients with post-bariatric hypoglycemia.

Vandana Singh

Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market

Guggenheim initiates Amylyx at Buy with $17 price forecast, citing PBH drug avexitide's Phase 3 potential and $2 billion+ market opportunity.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-126.58M

Investing Cash Flow (TTM)

-78.83M

Financing Cash Flow (TTM)

196.09M

Free Cash Flow (TTM)

-126.72M

Capital Expenditure (TTM)

-140.00K

Net Change in Cash (TTM)

-9.31M

Analyst Trends and Forecast

1

Apr

1

Jun

1

Jul

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.16B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

10.47

Earnings Yield % (TTM)

-6.28%

Earnings Yield % (FWD)

-6.63%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.15

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$49.33M

Debt to Equity

0.02

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$22.35

Close

$21.63

Volume / Avg.

1.59M / 1.64M

Day Range

$21.29 - $22.39

52 Wk Range

7.63 - 24.60

Market Cap

$2.39B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

57

Short Interest

15.62%

Days to Cover

6.84

About

Sector

Health Care

Industry

Pharmaceuticals

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neuro...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Amylyx Pharmaceuticals (AMLX) stock?

A

You can purchase shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Amylyx Pharmaceuticals (AMLX) competitors?

A

Other companies in Amylyx Pharmaceuticals’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).

Q

What is the forecast, or price target, for Amylyx Pharmaceuticals (AMLX) stock?

A

Amylyx Pharmaceuticals has a consensus price target of $20.42.

Q

What is the current price for Amylyx Pharmaceuticals (AMLX)?

A

The stock price for Amylyx Pharmaceuticals (NASDAQ: AMLX) is $21.5 last updated August 14, 2026 at 6:03 PM EDT.

Q

Does Amylyx Pharmaceuticals (AMLX) pay a dividend?

A

There are no upcoming dividends for Amylyx Pharmaceuticals.

Q

When is Amylyx Pharmaceuticals (NASDAQ:AMLX) reporting earnings?

A

Amylyx Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Amylyx Pharmaceuticals (AMLX) going to split?

A

There is no upcoming split for Amylyx Pharmaceuticals.

Q

What sector and industry does Amylyx Pharmaceuticals (AMLX) operate in?

A

Amylyx Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.